FDA Approved: VIMIZIM — Original Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approves BioMarin's Vimizim (elosulfase alfa) under an Original Biologics License Application for the treatment of Morquio A syndrome (MPS IVA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Iva

Drugs mentioned

• VIMIZIM (Elosulfase alfa)

Snippet

ORIG AP for VIMIZIM (ELOSULFASE ALFA)